



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-388-A)

RECEIVED
TECH CENTER 1600/2000
SEP 04 2002
Y

In the Application of:

Nolan et al.

Serial No.: 09/851,743

Filing Date: May 9, 2001

For: Methods for Testing Compounds Useful
In Treating Diabetic Complications

Examiner:

Group Art Unit: 1614

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned representative by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

Date: August 27, 2002

Kevin E. Noonan
Reg. No. 35,303